IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...

At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . Although uncommon, researchers recommend physicians are aware of the risk for delayed nodules in patients after ...

(RTTNews) - Allergan plc (AGN) said that it received U.S. Food and Drug Administration approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula ...

Please provide your email address to receive an email when new articles are posted on . Recent developments in cosmetic dermatology include the FDA clearance of Ulthera’s Cellfina System for long-term ...

Dr. Gary Gesualdi is recognized among the nation’s leading injectors and was handpicked to join an elite group of cosmetic physicians to receive early training and authorization to provide VOLUMA, ...

DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA ® XC, a hyaluronic acid gel ...